The history of the development of buprenorphine as an addiction therapeutic
The history of the development of buprenorphine as an addiction therapeutic
复制标题
DOI：
10.1111/j.1749-6632.2011.06352.x
复制
发表时间：
2012-01-01
期刊：
影响因子：
--
通讯作者：
Lovell, Anne M.
中科院分区：
文献类型：
--
作者：
Campbell, Nancy D.;Lovell, Anne M.
本文追溯了21世纪初激动剂-拮抗剂丁丙诺啡的成功，以及丁丙诺啡与纳洛酮的联合药物丁丙诺啡在更广泛的探索中发展成瘾治疗，始于20世纪20年代，作为一种非成瘾性镇痛药的探索。通过档案研究、文献分析和对当代参与者的访谈，本文将实验室和临床研究的社会组织置于国内外几个问题的融合中，包括研究伦理、药物监管、公众态度、围绕药物成瘾定义的紧张关系以及制药行业角色的演变。驱使丁丙诺啡拥护者的热情必须从以下方面来理解：(1)研究和药品制造的物质工作；(2)到20世纪70年代中期，丁丙诺啡作为一种解决成瘾治疗中许多问题的象征性作用；成瘾者作为患者的去污名化与个体化(3)公私伙伴关系的复杂配置。
This paper traces the early 21st century success of the agonist-antagonist buprenorphine and the combination drug buprenorphine with naloxone within the broader quest to develop addiction therapeutics that began in the 1920s as the search for a nonaddictive analgesic. Drawing on archival research, document analysis, and interviews with contemporary actors, this paper situates the social organization of laboratory-based and clinical research within the domestic and international confluence of several issues, including research ethics, drug regulation, public attitudes, tensions around definitions of drug addiction, and the evolving roles of the pharmaceutical industry. The fervor that drove the champions of buprenorphine must be understood in relation to (1) the material work of research and pharmaceutical manufacturing; (2) the symbolic role of buprenorphine as a solution to numerous problems with addiction treatment evident by the mid-1970s; the destigmatization and individualization of addicts as patients; and (3) the complex configurations of public and private partnerships.